0.273

7.91% 0.02

After Hours: .27 -0.003 -1.10%

Outlook Therapeutics Inc (OTLK)

Overview News Price History Financials Discussions Forecast Stock Split

Outlook Therapeutics Inc stock is traded at $0.273, with a volume of 2.67M. It is up +7.91% in the last 24 hours and down -30.71% over the past month. Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Previous Close:

$0.253

Open:

$0.247

24h Volume:

2.67M

Relative Volume:

1.00

Market Cap:

$28.56M

Revenue:

$297.50K

Net Income/Loss:

$-72.19M

P/E Ratio:

-0.1594

EPS:

-1.7127

Net Cash Flow:

$-54.39M

1W Performance:

+9.16%

1M Performance:

-30.71%

6M Performance:

-81.30%

1Y Performance:

-80.36%

1-Day Range:

$0.247

$0.276

1-Week Range:

$0.21

$0.276

52-Week Range:

$0.1611

$3.39

Outlook Therapeutics Inc Stock (OTLK) Company Profile

Name

Outlook Therapeutics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

(609) 619-3990

Address

111 S. WOOD AVENUE, ISELIN, NJ

Employee

Twitter

Next Earnings Date

2024-08-14

Latest SEC Filings

OTLK's Discussions on Twitter

Compare OTLK vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
OTLK Outlook Therapeutics Inc	0.273	26.47M	297.50K	-72.19M	-54.39M	-1.7127
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-29-25	Downgrade	H.C. Wainwright	Buy → Neutral
Aug-28-25	Downgrade	Guggenheim	Buy → Neutral
Dec-02-24	Downgrade	Chardan Capital Markets	Buy → Neutral
Mar-27-24	Upgrade	BTIG Research	Neutral → Buy
Feb-15-24	Upgrade	Chardan Capital Markets	Neutral → Buy
Jan-25-24	Upgrade	Guggenheim	Neutral → Buy
Dec-27-23	Upgrade	CapitalOne	Equal Weight → Overweight
Aug-31-23	Downgrade	Chardan Capital Markets	Buy → Neutral
Aug-31-23	Downgrade	H.C. Wainwright	Buy → Neutral
Aug-30-23	Downgrade	BTIG Research	Buy → Neutral
Aug-30-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Aug-30-23	Downgrade	CapitalOne	Overweight → Equal Weight
Aug-30-23	Downgrade	Guggenheim	Buy → Neutral
Jul-13-23	Initiated	CapitalOne	Overweight
Apr-03-23	Initiated	Guggenheim	Buy
Feb-06-23	Initiated	Cantor Fitzgerald	Overweight
Oct-31-22	Initiated	BTIG Research	Buy
Sep-13-22	Initiated	Chardan Capital Markets	Buy
Sep-11-19	Initiated	Ladenburg Thalmann	Buy
May-16-19	Initiated	Oppenheimer	Outperform
Apr-22-19	Initiated	Ascendiant Capital Markets	Buy

View All

Outlook Therapeutics Inc Stock (OTLK) Latest News

Apr 13, 2026

Breakouts Watch: Will Outlook Therapeutics Inc benefit from AI trends2026 Big Picture & Low Drawdown Trading Strategies - baoquankhu1.vn

Apr 13, 2026

Apr 10, 2026

Plus Therapeutics Inc (PSTV) Stock Price, Quote, News & History - Benzinga

Apr 10, 2026

Apr 08, 2026

H.C. Wainwright Maintains Outlook Therapeutics(OTLK.US) With Hold Rating, Maintains Target Price $0.5 - Moomoo

Apr 08, 2026

Outlook Therapeutics files dispute resolution request with FDA By Investing.com - Investing.com India

Apr 08, 2026

Outlook Therapeutics’ Formal Dispute Resolution for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA for Wet AMD Approval Pathway 1 - Minichart

Apr 08, 2026

Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA - Sahm

Apr 08, 2026

Outlook Therapeutics Files FDA Resolution Request After Rejection For Vision Loss Drug - Sahm

Apr 08, 2026

Apr 07, 2026

Outlook Therapeutics Pursues FDA Dispute Resolution for ONS-5010 - TipRanks

Apr 07, 2026

FDA accepts Outlook Therapeutics (NASDAQ: OTLK) dispute request on LYTENAVA - Stock Titan

Apr 07, 2026

Outlook Therapeutics request for FDA dispute resolution on ONS-5010 accepted - Traders Union

Apr 07, 2026

Outlook Therapeutics (OTLK) Seeks FDA Review for ONS-5010 Approval - GuruFocus

Apr 07, 2026

Outlook Therapeutics files dispute resolution request with FDA - Investing.com

Apr 07, 2026

Outlook Therapeutics Announces Formal Dispute Resolution Request For Ons-5010/Lytenava™ (Bevacizumab-Vikg) Accepted By FDA - TradingView — Track All Markets

Apr 07, 2026

FDA accepts Outlook dispute request, sets April eye-drug meeting - Stock Titan

Apr 07, 2026

Apr 06, 2026

Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA (bevacizumab-vikg) Accepted by FDA - Bitget

Apr 06, 2026

Outlook Therapeutics (OTLK) price target decreased by 27.91% to 3.95 - msn.com

Apr 06, 2026

Apr 05, 2026